Imalieva 400mg Tablet: Precision Tyrosine Kinase Inhibition for Chronic Hematologic Malignancies Are you searching for a reliable Imalieva 400mg Tablet exporter from India? Ernest Oncology, a specialized division of the Group of Ernest Pharmaceutical Pvt. Ltd., is a premier global supplier and bulk distributor of targeted kinase inhibitors. We maintain an agile and secure supply chain for London (UK), Washington (USA), Canberra (Australia), and South Africa, ensuring that critical oncology medications reach institutional pharmacies with 100% pharmaceutical integrity. Detailed Product Profile: What is Imalieva 400mg? Imalieva 400mg is an oral targeted therapy containing the active pharmaceutical ingredient Imatinib Mesylate. Manufactured by Allieva Pharma Pvt Ltd, this 400mg tablet is a breakthrough in the treatment of specific blood cancers and solid tumors. It belongs to the class of medications known as tyrosine kinase inhibitors (TKIs), which revolutionized oncology by targeting cancer cells at the molecular level with minimal damage to healthy cells. 1. Therapeutic Indications Chronic Myeloid Leukemia (CML): Specifically for Philadelphia chromosome-positive (Ph+) CML in chronic, accelerated, or blast crisis phases. Acute Lymphoblastic Leukemia (ALL): Used for adult and pediatric patients with Ph+ ALL, often in combination with chemotherapy. Gastrointestinal Stromal Tumors (GIST): Indicated for the treatment of Kit (CD117) positive unresectable and/or metastatic malignant GIST. Myelodysplastic/Myeloproliferative Diseases (MDS/MPD): Associated with PDGFR gene re-arrangements. Hypereosinophilic Syndrome (HES) and/or Chronic Eosinophilic Leukemia (CEL): For adult patients with specific genetic markers. 2. Mechanism of Action: Molecular Precision Enzyme Blocking: It binds to the ATP-binding site of the Bcr-Abl tyrosine kinase enzyme. This enzyme is the “on-switch“ that tells cancer cells to multiply uncontrollably. Halting Proliferation: By blocking this switch, Imalieva prevents the phosphorylation of proteins involved in signal transduction, thereby stopping the growth of the tumor. Apoptosis Induction: It encourages programmed cell death (apoptosis) in the malignant cell lines without harming the surrounding normal tissues. 3. Administration and Patient Management Standard Dosing: For most indications, the standard dose is 400mg once daily. Administration: Must be taken with a meal and a large glass of water to minimize gastrointestinal irritation. Consistency: For maximum therapeutic benefit, the medication should be taken at the same time every day. Clinical Side Effects & Safety Monitoring Fluid Retention: Monitoring for periorbital edema (swelling around eyes) or peripheral edema. Hematological Safety: Potential for Neutropenia or Thrombocytopenia; frequent CBC (Complete Blood Count) tests are mandatory. Hepatotoxicity: Regular Liver Function Tests (LFTs) are required as Imatinib can affect liver enzymes. Gastrointestinal Health: Patients may experience nausea, vomiting, or diarrhea, which can usually be managed with supportive care. Why Source Imalieva 400mg from Ernest Oncology? Verified Authenticity: Direct sourcing of Allieva Pharma’s Imalieva with full batch-specific COA and traceability. Logistics Authority: Expert handling of complex import/export regulations for USA, UK, Australia, and South Africa. Wholesale Solutions: Competitive bulk pricing for hospital groups, specialty pharmacies, and regional distributors. Regulatory Compliance: Every shipment includes GMP certificates and comprehensive B2B documentation to ensure global standards. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 🌐 Websites: www.oncologymedicinesupplier.com www.ernestimpex.com www.ernestvision.com www.ernestpharmaceuticals.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct Link: https://wa.me/919359902383